Want to see GB:HEMO full AI Analyst Report?
Top Page
HemoGenyx Pharmaceuticals Plc
(LSE:HEMO)
Select Model
Select Model
Rating:45Neutral
Price Target:
490.00 p
▼(-11.87% Downside)
Action:Reiterated
Date:08/26/26
The score is primarily held down by weak financial performance (no revenue, continued losses, cash burn, and leverage relative to a reduced equity base). Technicals also remain bearish with the price below major moving averages and negative MACD, despite near-oversold readings. Corporate events are a relative positive (clinical collaboration and capital flexibility), but potential dilution offsets some of that benefit.
Positive Factors
Clinical Collaboration
The hospital collaboration could strengthen HemoGenyx’s clinical development platform by enabling broader FLT3 CAR-T work and additional data generation. Over the next several months, stronger clinical evidence may improve the credibility of its hematology pipeline and support future development or partnering options.
Negative Factors
No Revenue
The absence of reported revenue indicates that HemoGenyx remains pre-commercial and has not yet demonstrated a recurring operating income stream. This leaves funding dependent on external capital while clinical programs progress, making the business model less resilient until products or other revenue sources emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Collaboration
The hospital collaboration could strengthen HemoGenyx’s clinical development platform by enabling broader FLT3 CAR-T work and additional data generation. Over the next several months, stronger clinical evidence may improve the credibility of its hematology pipeline and support future development or partnering options.
Read all positive factors
HemoGenyx Pharmaceuticals Plc (HEMO) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£35.36M
Dividend YieldN/A
Average Volume (3M)13.11K
Price to Earnings (P/E)―
Beta (1Y)0.14
Revenue GrowthN/A
EPS Growth-28.29%
CountryUK
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.21
Shares Outstanding6,799,961
10 Day Avg. Volume19,087
30 Day Avg. Volume13,110
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)21.26
Price to Sales (P/S)0.00
P/FCF Ratio-7.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HemoGenyx Pharmaceuticals Plc Business Overview & Revenue Model
Company Description
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel soluti...
How the Company Makes Money
Publicly available information in the provided context is insufficient to describe HemoGenyx Pharmaceuticals Plc’s specific, current revenue model and key revenue streams in a factual, detailed way (e.g., whether it earns revenue from product sale...
HemoGenyx Pharmaceuticals Plc Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
26
Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -588.75K | -639.28K | -645.68K | -2.60M | -283.65K |
| EBITDA | -4.07M | -4.71M | -5.73M | -3.42M | -2.39M |
| Net Income | -9.76M | -5.62M | -6.69M | -3.98M | -5.10M |
Balance Sheet | |||||
| Total Assets | 4.18M | 4.21M | 6.11M | 7.09M | 8.52M |
| Cash, Cash Equivalents and Short-Term Investments | 1.59M | 159.26K | 1.25M | 2.53M | 6.84M |
| Total Debt | 2.00M | 2.62M | 2.95M | 3.42M | 10.15K |
| Total Liabilities | 3.03M | 3.36M | 3.32M | 3.85M | 352.84K |
| Stockholders Equity | 1.20M | 897.51K | 2.82M | 3.28M | 8.19M |
Cash Flow | |||||
| Free Cash Flow | -3.45M | -4.13M | -6.22M | -3.34M | -3.45M |
| Operating Cash Flow | -3.45M | -4.12M | -6.11M | -2.91M | -2.63M |
| Investing Cash Flow | -6.80K | -24.90K | -31.94K | -420.25K | -938.95K |
| Financing Cash Flow | 4.89M | 3.08M | 4.45M | -110.14K | 8.78M |
HemoGenyx Pharmaceuticals Plc Technical Analysis
Negative
556.00
Price Trends
667.39
Negative
702.03
Negative
758.38
Negative
Market Momentum
-45.35
Positive
28.17
Positive
17.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HEMO, the sentiment is Negative. The current price of 556 is below the 20-day moving average (MA) of 581.42, below the 50-day MA of 667.39, and below the 200-day MA of 758.38, indicating a bearish trend. The MACD of -45.35 indicates Positive momentum. The RSI at 28.17 is Positive, neither overbought nor oversold. The STOCH value of 17.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:HEMO.
HemoGenyx Pharmaceuticals Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £47.50M | -7.84 | -14.65% | 2.90% | -25.43% | -155.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £62.98M | -8.87 | -55.47% | ― | ― | 19.83% | |
51 Neutral | £28.88M | 43.47 | 14.26% | ― | ― | ― | |
46 Neutral | £13.01M | -3.75 | -135.35% | ― | 13.42% | 65.63% | |
45 Neutral | £35.36M | -2.35 | -2807.75% | ― | ― | -28.29% | |
42 Neutral | £22.46M | -9.73 | -353.21% | 17.86% | ― | 36.67% |
* Healthcare Sector Average
GB:HEMO
HemoGenyx Pharmaceuticals Plc
502.50
-228.50
-31.26%
GB:IMM
ImmuPharma
4.00
-7.13
-64.04%
GB:HVO
Open Orphan Plc
7.15
-2.65
-27.04%
GB:POLB
Poolbeg Pharma Ltd.
8.30
4.00
93.02%
GB:AREC
Arecor Therapeutics PLC
77.50
5.00
6.90%
GB:APTA
Aptamer Group Plc
0.38
-0.77
-67.39%
HemoGenyx Pharmaceuticals Plc Corporate Events
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Hemogenyx Raises £291,665 Through Warrant Exercises Ahead of LSE Admission
Positive
Sep 3, 2026
Hemogenyx Pharmaceuticals plc has received notices to exercise warrants over 96,825 new ordinary shares, at prices between 180p and 350p, raising £291,665 in fresh capital. The new shares will rank pari passu with existing stock and are expec...
Business Operations and Strategy
Hemogenyx Expands FLT3 CAR-T Effort With Vilnius Hospital Collaboration
Positive
Jul 29, 2026
Hemogenyx Pharmaceuticals has signed a Letter of Intent with the National Cancer Centre at Vilnius University Hospital Santaros Klinikos to collaborate on FLT3-positive acute myeloid leukemia and myelodysplastic syndromes. The partnership combines...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingShareholder Meetings
Hemogenyx Wins Full Shareholder Backing at AGM, Secures New Capital Flexibility
Positive
Jul 1, 2026
Hemogenyx Pharmaceuticals reported that shareholders approved all resolutions at its latest annual general meeting, including the adoption of the 2025 financial accounts and the directors’ remuneration report. Investors also backed the reapp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.